3SBio (SEHK:1530) - Cotización, noticias y análisis

Resumen de acción 1530

3SBio Inc. es un holding de inversiones que desarrolla, produce, comercializa y vende productos biofarmacéuticos en China continental y a escala internacional.

Acerca de la empresa

1530 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	2/6
Financial Health	6/6
Dividends	2/6

Recompensas

Cotiza un 57.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 12.6%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Historial de dividendos inestable

Competidores de 3SBio Inc.

Shanghai Haohai Biological Technology

SEHK:6826

HK$15.5b

Shanghai Henlius Biotech

SEHK:2696

HK$9.1b

CK Life Sciences Int'l. (Holdings)

SEHK:775

HK$3.8b

Essex Bio-Technology

SEHK:1061

HK$1.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for 3SBio
Historical stock prices
Current Share Price	HK$6.58
52 Week High	HK$8.10
52 Week Low	HK$4.91
Beta	0.78
1 Month Change	8.22%
3 Month Change	13.25%
1 Year Change	-17.23%
3 Year Change	-6.53%
5 Year Change	-51.19%
Change since IPO	-29.63%

Noticias y actualizaciones recientes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Jan 26

Recent updates

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

Rentabilidad de los accionistas

	1530	HK Biotechs	Mercado HK
7D	8.8%	8.1%	2.8%
1Y	-17.2%	-34.2%	-8.1%

Rentabilidad vs. Industria: 1530 superó al sector Hong Kong Biotechs , que obtuvo un rendimiento del -38.9% el año pasado.

Rentabilidad vs. Mercado: 1530 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.1% el año pasado.

Volatilidad de los precios

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement	7.1%
Biotechs Industry Average Movement	9.4%
Market Average Movement	7.5%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.6%

Precio estable de las acciones: 1530 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 1530 (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1993	5,411	Jing Lou	www.3sbio.com

3SBio Inc, un holding de inversiones, desarrolla, produce, comercializa y vende productos biofarmacéuticos en China continental y a escala internacional. La empresa ofrece TPIAO, una trombopoyetina humana recombinante para tratar la trombopenia inducida por la quimioterapia y la trombocitopenia inmunitaria; Cipterbin, un anticuerpo monoclonal anti-HER2 para el tratamiento del cáncer de mama metastásico HER2-positivo en combinación con quimioterapia; Interferon, un interferón a2a humano inyectable; e Inleusin, para el tratamiento del carcinoma de células renales, el melanoma, la acumulación de líquido torácico causada por el cáncer y la tuberculosis. También ofrece YISAIPU, inhibidor del factor de necrosis tumoral de fusión receptor-anticuerpo; Mendi-minoxidil tintura, medicamento externo de venta libre para el tratamiento de la caída del cabello; EPIAO y SEPO, eritropoyetina inyectable; SPARIN, heparina cálcica inyectable de bajo peso molecular; y Xenopax, anticuerpo monoclonal recombinante humanizado anti-cd25 inyectable para la prevención del rechazo agudo tras el trasplante renal.

Resumen de fundamentos de 3SBio Inc.

¿Cómo se comparan los beneficios e ingresos de 3SBio con su capitalización de mercado?
Estadísticas fundamentales de 1530
Capitalización bursátil	HK$15.67b
Beneficios(TTM)	HK$1.67b
Ingresos (TTM)	HK$8.44b

9.4x

Ratio precio-beneficio (PE)

1.9x

Ratio precio-ventas (PS)

¿Está 1530 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 1530
Ingresos	CN¥7.82b
Coste de los ingresos	CN¥1.17b
Beneficio bruto	CN¥6.64b
Otros gastos	CN¥5.09b
Beneficios	CN¥1.55b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.65
Margen bruto	84.98%
Margen de beneficio neto	19.82%
Ratio deuda/patrimonio	29.1%

¿Cómo se ha desempeñado 1530 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.8%

Rentabilidad actual por dividendo

36%

Ratio de pagos

¿Paga 1530 dividendos fiables?

Ver historial de dividendos e índices de referencia de 1530

¿Cuándo hay que comprar 1530 para recibir un próximo dividendo?
fechas de dividendos de 3SBio
Fecha ex dividendo	Jul 22 2024
Fecha de pago de dividendos	Aug 05 2024
Días hasta ex dividendo	80 days
Días hasta la fecha de pago de dividendos	94 days

¿Paga 1530 dividendos fiables?

Ver historial de dividendos e índices de referencia de 1530

Resumen de acción 1530

Recompensas

Análisis de riesgos

Competidores de 3SBio Inc.

SEHK:6826

HK$15.5b

SEHK:2696

HK$9.1b

SEHK:775

HK$3.8b

SEHK:1061

HK$1.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Recent updates

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company